BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32339358)

  • 1. PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.
    Wang B; Gan W; Han X; Li D
    Cell Biol Int; 2020 Aug; 44(8):1727-1733. PubMed ID: 32339358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
    Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
    Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
    Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
    Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
    Wang B; Gan W; Han X; Liu N; Ma T; Li D
    Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
    Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
    PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
    Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
    J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
    Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
    Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
    Neha ; Das P; Verma SP
    Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.